🇺🇸 FDA
Pipeline program

SPR206

SPR206-103

Phase 1 small_molecule completed

Quick answer

SPR206 for Renal Impairment is a Phase 1 program (small_molecule) at Spero Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Spero Therapeutics
Indication
Renal Impairment
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials